Explore

Micron Biomedical Secures Federal Contract for Radiation Medical Countermeasure

Micron Biomedical Secures Federal Contract for Radiation Medical Countermeasure

Micron Biomedical, a clinical-stage life science company, has been awarded a $4.5 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). The contract is aimed at developing the first dissolvable microarray medical countermeasure against radiation injury. This innovative approach is designed to enhance national preparedness against nuclear threats by providing a thermostable treatment for Acute Radiation Syndrome (ARS) that can be administered by minimally-trained personnel or self-administered. The technology involves a dissolvable microarray platform that delivers medications painlessly through the skin, eliminating the need for traditional injections and sharps waste. This development is part of a broader effort to improve the rapid deployment of medical countermeasures in emergency scenarios.

Micron Biomedical Awarded $4.5 Million Contract for Radiation Countermeasure Development

Micron Biomedical Awarded $4.5 Million Contract for Radiation Countermeasure Development

Micron Biomedical Awarded $4.5 Million Contract for Radiation Countermeasure Development

Former FDA Official Warns Against Bagged Salads Amid Cyclospora Outbreak

Former FDA Official Warns Against Bagged Salads Amid Cyclospora Outbreak

A former FDA food safety chief has advised consumers to avoid bagged salads due to a surge in cyclospora infections across the U.S. Susan Mayne, a former director at the FDA, highlighted the risk of contamination in prepackaged leafy greens. The ongoing investigation into the outbreak, which has affected multiple states, is focused on identifying the source of the parasite Cyclospora cayetanensis. The outbreak has been linked to fresh produce, including leafy greens, herbs, and berries, causing gastrointestinal illness characterized by severe diarrhea and cramping.

FDA Retracts Cyclospora Test on Recalled Lettuce Amid Consumer Reports Criticism

FDA Retracts Cyclospora Test on Recalled Lettuce Amid Consumer Reports Criticism

The FDA has retracted its positive Cyclospora test on recalled lettuce, initially linked to a significant U.S. outbreak. The retraction follows a re-evaluation that deemed the test a false positive. Despite this, the recall remains in place due to epidemiological evidence connecting the lettuce to the outbreak. Consumer Reports criticized the recall notice for using internal abbreviations instead of full brand names, making it difficult for consumers to identify affected products. The recall involves products from Taylor Farms, including those sold under Walmart's Marketside brand. The outbreak has resulted in nearly 2,000 confirmed cases across nine states, with the CDC investigating additional cases.

Cyclospora Outbreak Prompts Shift in American Produce Consumption

Cyclospora Outbreak Prompts Shift in American Produce Consumption

A Cyclospora outbreak linked to recalled iceberg lettuce has led to a significant change in consumer behavior across the United States. According to a CBS News/YouGov survey, 40% of Americans are now buying or eating less fresh produce due to concerns over food safety. The outbreak, traced back to Taylor Farms' iceberg lettuce sourced from central Mexico, has resulted in 1,947 illnesses across nine states, with 98 hospitalizations reported. Despite no confirmed positive tests for Cyclospora in Taylor Farms' products, the company has recalled all potentially affected lettuce and suspended production in the implicated region. The Centers for Disease Control and Prevention (CDC) is monitoring the situation, having recorded over 4,000 confirmed cases of cyclosporiasis since May 1.

FDA Advisers Vote to Add Peptides to Drug Compounding List Amid Controversy

FDA Advisers Vote to Add Peptides to Drug Compounding List Amid Controversy

The FDA's Pharmacy Compounding Advisory Committee has voted to add six peptides to a drug compounding list, allowing specialty pharmacies to use them in custom medications. The decision, which is non-binding, will require FDA approval. The peptides, including BPC-157 and TB-500, have gained popularity online despite limited clinical data. The vote has sparked debate between FDA scientists, who oppose the addition due to safety concerns, and committee members who argue it could reduce harm by steering consumers away from unregulated markets.

FDA Panel Supports Compounding of Select Peptides Amid Controversy

FDA Panel Supports Compounding of Select Peptides Amid Controversy

An FDA advisory panel has recommended allowing compounding pharmacies to manufacture the peptides epitalon and semax, while narrowly voting against emideltide. This decision follows a two-day meeting that highlighted tensions between the Make America Healthy Again movement and mainstream scientists. The panel's recommendations come despite FDA staff's concerns about the lack of clinical evidence for these peptides' safety and efficacy. The decision now awaits further action from the FDA, which may or may not follow the panel's advice.

FDA Panel Supports Easier Access to Peptide Therapies Amid Safety Concerns

FDA Panel Supports Easier Access to Peptide Therapies Amid Safety Concerns

An advisory panel to the Food and Drug Administration (FDA) has recommended easing restrictions on peptide therapies, allowing specialized pharmacies in the U.S. to manufacture these compounds. Despite the FDA scientists' concerns about safety and lack of large-scale human trials, the panel voted in favor of making these experimental drugs more accessible. Peptides like BPC-157 and TB-500 are popular for their purported benefits in athletic performance and longevity. The decision comes amid a growing unregulated market where Americans are using unvetted substances sourced from overseas. Health Secretary Robert F. Kennedy Jr. has endorsed the move, emphasizing the need for a regulated market to ensure safety.

Salmonella Outbreak Linked to Recalled Eggs Affects 98 People Across 17 States

Salmonella Outbreak Linked to Recalled Eggs Affects 98 People Across 17 States

A salmonella outbreak linked to recalled eggs has sickened 98 people in 17 states since November, according to the U.S. Food and Drug Administration. The outbreak has resulted in 26 hospitalizations, though no deaths have been reported. The eggs, distributed by Midwest Poultry Services, were sold under various brand names and have been recalled. The affected eggs were distributed to several states, including Texas and Louisiana, and were sold in major grocery chains like Kroger and Brookshire Grocery. Consumers are advised to check for recalled eggs and dispose of them or return them for a refund.

FDA Links Salmonella Outbreak to Recalled Eggs from Texas Producer

FDA Links Salmonella Outbreak to Recalled Eggs from Texas Producer

The FDA has linked a salmonella outbreak affecting nearly 100 people in 17 states to eggs recalled by Midwest Poultry Services. The company voluntarily recalled approximately 19 million eggs produced in Texas due to potential contamination. The eggs, sold under various brand names, have sell-by dates between July 20 and August 17. The outbreak has resulted in 26 hospitalizations, though no deaths have been reported. Consumers are advised to check for recalled eggs and return them for a refund. The FDA continues to investigate other potential sources of the outbreak.

FDA Recalls Levothyroxine Sodium Tablets Due to Subpotency Concerns

FDA Recalls Levothyroxine Sodium Tablets Due to Subpotency Concerns

The Food and Drug Administration (FDA) has issued a Class II recall for certain lots of levothyroxine sodium tablets distributed by Major Pharmaceuticals. The recall is due to the tablets being 'subpotent,' meaning they may not deliver the full prescribed dose. Levothyroxine sodium is commonly used to treat underactive thyroid and goiter. The affected lots include 10-count blister packs and 100-tablet cartons with dosages ranging from 25 micrograms to 150 micrograms. The expiration dates for these lots range from July 2026 to January 2027. Patients are advised to check their medication against the FDA's list of affected lot numbers and consult their healthcare provider if there is a match. The FDA assures that any health effects from the lower dose are expected to be temporary and reversible.

Semax's Role in Cognitive Recovery and Its Regulatory Status in the U.S.

Semax's Role in Cognitive Recovery and Its Regulatory Status in the U.S.

Semax, a synthetic peptide developed in Russia, is gaining attention for its potential cognitive benefits, including focus and recovery. Despite its popularity in nootropic communities, Semax is not FDA-approved in the United States and is primarily available as a research chemical. The peptide is believed to enhance cognitive function by upregulating brain-derived neurotrophic factor (BDNF), which supports neuron survival and plasticity. However, most research supporting these claims originates from Russian studies, making it difficult for Western researchers to verify the findings. Semax is often used in Russia for stroke rehabilitation and cognitive impairment, but its use in the U.S. remains limited due to regulatory uncertainties and the lack of long-term safety data.